Grant R. Zimmermann

Managing Director of Business Development, Blavatnik Biomedical Accelerator

Displaying: 41 - 50 of 67 Results

Invention

A fusion intermediate state of HIV-1 gp41, targeted by broadly neutralizing antibodies, for purposes of vaccination

HIV infection generally induces a strong antibody response to the envelope glycoprotein, the sole antigen on the virion surface. Most of the induced antibodies are ineffective in preventing infection, however, as they are either non-neutralizing or…

Investigators

  • Stephen C. Harrison
  • Gary H. Frey
  • Bing Chen

Invention

Method for producing site-specific recombination of DNA in a transgenic non-human mammal at chromosomal regions containing Flp-recognition sites

A method is disclosed for producing site-specific recombination of DNA in a transgenic non-human mammal at chromosomal regions containing Flp-recognition sites (e.g., a DNA sequence containing an FRT site). The invention in particular discloses the…

Investigators

  • Susan M. Dymecki
  • A. Francis Stewart

Invention

Gluconeogenesis as a pro-survival treatment for neurons under stress

A series of AAV-based gene therapy approaches to reprogram certain metabolic enzymes in rod and cone cells in the eye to promote survival in degenerative conditions such as retinitis pigmentosa. Additionally, an independent series of such vectors…

Investigators

  • Constance L. Cepko
  • Claudio Punzo

Invention

Metabolic labeling and direct imaging of choline-containing phospholipids in vivo

A functional analog of a metabolic phospholipid precursor has been devised that, when contacted with cells, becomes incorporated into a cells endogenous phospholipids through cellular metabolic processes. The resulting phospholipids contain a moiety…

Investigators

  • Adrian Salic

Invention

anti-MARCO monoclonal antibody

The monoclonal antibody recognizes the Macrophage Receptor with Collagenous structure (MARCO). The scavenger receptors (SRs) expressed by macrophages are thought to play an important role in the immune response against bacteria by mediating binding…

Investigators

  • Lester Kobzik
  • Aiyappa M. Palecanda

Invention

Homozygous IKKepsilon knockout mouse as an animal model for influenza virus infection

Homozygous IKKepsilon (inhibitor of kappaB kinase epsilon) mutant mice are used as animal models for influenza virus infection. Homozygous deletion results in a complete loss of the endogenous kinase function in lung, spleen, and embryonic…

Investigators

  • Thomas Maniatis
  • Benjamin R. tenOever

Invention

Absolute quantification of Proteins (AQUA)

This invention provides methods, reagents and kits for obtaining absolute quantification of proteins and their modifications directly from cell lysates. In particular, the invention provides peptide internal standards for use in high performance…

Investigators

  • Steven P. Gygi
  • Scott A. Gerber

Invention

Protein-based therapies using quantitatively designed proteins

A bipartite, quantitatively designed protein having two discrete ligands and a linker; one ligand having the ability to strongly bind to a particular cell, the other having the ability to affect a target only when the previous ligand binds. For many…

Investigators

  • Pamela A. Silver
  • Pablo Cironi
  • David G. Miguez

Research Tool

Glar2 Knock Out Mice

Mice homozygous for this targeted mutation are viable and fertile and do not display any gross physical or behavioral abnormalities. There is no identifiable phenotype in these mice. Expression is eliminated in the brain as determined by RT-PCR and…

Investigators

  • Connie Cepko

Research Tool

ACTB:FLPe Transgenic Mice

This transgenic strain expresses a variant of the Saccharomyces cerevisiae FLP1 recombinase gene under the direction of the human ACTB promoter. The FLPe recombinase variant exhibits enhanced thermostability with recombination activity being…

Investigators

  • Susan M. Dymecki

Page 5 of 7